Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ASCO GU 2018: Renal Cell Carcinoma News Program

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress.

Moderator Catherine Hood and a panel of international experts discuss the following topics:

  • Adjuvant systemic therapy
  • Cabozantinib in the first line treatment of metastatic RCC
  • The NIVOREN trial that investigates nivolumab in a ‘real world setting’
  • Combination treatments with VEGF and PD1/PD-L1 inhibition
  • Advances in treatment for papillary RCC


  • Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston
  • Daniel George, MD, medical oncologist, Duke Cancer Center, Durham
  • Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax
  • Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte

Moderator: Catherine Hood

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

E-learnings 04/03/2019

E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC.  ‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’ Topics that are discussed in this e-learning are: When are we ready for adjuvant therapy? What is the role of cytoreductive nephrectomy in mRCC? How to choose from the available options for first, second, and third line treatment? What may be the impact of immunotherapy and novel TKIs on the treatment algorithm? Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL

Congress news 13/12/2018

EMUC 2018: Frail patients and the CARMENA trial

Dr. Umberto Capitanio, urologist at the IRCCS Ospedale San Raffaele in Italy and chief editor of the kidney cancer section of the UROONCO educational platform, talks about the EMUC 2018 discussion about frail patients. Furthermore he mentions the discussion about the Carmena trial in which nephrectomy plus adjuvant sunitinib is compared to sunitinib alone in patients with metastatic renal cell cancer.

Meet the author 12/09/2018

E-learning: Quarterly Focus on Genitourinary Cancer | RCC

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this second episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Renal Cell Carcinoma from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Prof. John Haanen, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Hans Westgeest, MD, medical oncologist, Amphia Ziekenhuis, Breda Astrid van der Veldt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam Program: Invited speaker: Kathleen Mahoney, MD, PhD, medical oncologist, Beth Israel Deaconess Medical Center, Boston Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma N Engl J Med 378, 2018 Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Nature Medicine 24, 2018

Congress news 22/03/2018

ASCO GU 2018: Progression after IO combination regimens mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined the clinical outcome of patients with metastatic renal cell carcinoma progressing on frontline immune-oncology based combination regimens.

Congress news 22/03/2018

ASCO GU 2018: Oligoprogressive mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined what the impact was of switching systemic treatment after radiosurgery for oligoprogressive, metastatic renal cell carcinoma.

Congress news 22/03/2018

ASCO GU 2017: RCC news

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. The final congress day was dedicated to renal cell carcinoma. A panel of American experts will bring you the day’s highlights, which include: circulating tumor DNA frontline systemic therapy (CABOSUN, IMmotion) TKI+immunotherapy active surveillance in localized and advanced disease imaging and biomarkers for the diagnosis and monitoring of RCC cryoablation adjuvant treatment for localized tumors (ASSURE, S-TRAC) hereditary renal cancer Speakers: Prof. Eric Jonasch MD, medical oncologist, University of Texas MD Anderson cancer center, Houston TX Sumanta Pal MD, medical oncologist, City of Hope, Duarte CA Prof. Mohamad Allaf MD, urologic oncologist, John Hopkins School of Medicine, Baltimore MD Moderator: Catherine Hood PhD The news program includes an interview with prof. Thomas Powles (Barts and the London School of Medicine, UK) on the results of the IMmotion trial and his expectations for the future of atezolizumab in RCC.

Congress news 22/03/2018


Dr. Kim Chi, medical oncologist at the BC Cancer Agency in Vancouver, summarizes the results of the LATITUDE trial and the recently published patient-reported outcomes and health-related quality of life.

Congress news 18/02/2017

‚ÄčASCO GU 2017: RT versus surgery in Gleason 9-10 Pca

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Amar Kishan Poster: A7 - Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era